A Phase II, Randomized, Open-Label, Controlled, Dose-Elevation, Multicenter Trial of an Investigational Drug for the Prevention of Diarrhea Associated With Irinotecan/5FU/Leucovorin Chemotherapy in Patients With Previously Untreated Metastatic Colorectal Cancer
Other specific inclusion/exclusion criteria may apply. In order to determine eligibility,
further examination by the investigator is necessary.
Interventional
Primary Purpose: Treatment
United States: Food and Drug Administration
440E-ONC-0020-315
NCT00040391
Name | Location |
---|---|
Research Center | Berkeley, California 94704 |
Research Center | West Boylston, Massachusetts 01583 |
Research Center | Ann Arbor, Michigan 48109 |
Research Center | Nashville, Tennessee 37232-6868 |
Research Center | Arlington, Texas 76012 |
Research Center | Cleveland, Ohio 44106 |
Research Center | Marshfield, Wisconsin 54449 |
Research Center | Little Rock, Arkansas 72205 |
Research Center | Jacksonville, Florida 32207 |
Research Center | New Orleans, Louisiana 70115 |
Research Center | Scarborough, Maine 04074-9308 |
Research Center | Minneapolis, Minnesota 55455 |
Research Center | St. Joseph, Missouri 64507 |
Research Center | Las Vegas, Nevada 89106 |
Research Center | East Setauket, New York 11733 |
Research Center | Burlington, North Carolina 27216 |
Research Center | Lancaster, Pennsylvania 17605 |
Research Center | Charleston, South Carolina 29403 |